Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2834 http://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Earnings Season Makes Good First Impression - Oct 16th, 2019 1:15 pm
Alnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society - Oct 15th, 2019 10:00 am
Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy - Oct 10th, 2019 11:30 am
With eyes on IPO, muscular dystrophy startup names new CEO - Oct 1st, 2019 10:31 am
If You Had Bought Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Three Years Ago You'd Have Made 14% - Sep 27th, 2019 11:27 am
Medicines Company's Inclisiran Succeeds in Pivotal Studies - Sep 26th, 2019 4:05 pm
Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference - Sep 26th, 2019 12:30 pm
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent - Sep 23rd, 2019 4:08 pm
Alnylam Focuses on Pipeline Development Amid Competition - Sep 19th, 2019 3:02 pm
Alnylam Begins Phase III Study on Onpattro for New Indication - Sep 17th, 2019 2:27 pm
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy - Sep 16th, 2019 11:30 am
What Makes Alnylam (ALNY) a New Buy Stock - Sep 13th, 2019 1:00 pm
Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy - Sep 13th, 2019 11:30 am
1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day - Sep 11th, 2019 12:30 pm
Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias - Sep 10th, 2019 9:30 am
3 Biotech Stocks That Could Soar This Week - Sep 9th, 2019 1:31 pm
Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy - Sep 6th, 2019 7:06 pm
Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series - Sep 6th, 2019 11:30 am
Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report? - Sep 5th, 2019 1:31 pm